miR-155 Directly Targets MARCH7 and Modulates Viability and Invasive Phenotypes in Breast Cancer Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188092 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Xiaohua Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, School of Medicine, Shaoguan University, Shaoguan 512026, China. Hauptthemen laut MEDLINE: MicroRNAs, Breast Neoplasms, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shaoguan University, 2023 Shaoguan Social Development Science and Technology Collaborative Innovation System Project Supporting Scientific Researchers, 2023 Shaoguan Social Development Science and Technology Collaborative Innovation System Project for Supporting Scientific Researchers.
Abstract (Originalsprache)
miR-155 is an oncogenic microRNA implicated in breast cancer, but its downstream post-transcriptional targets remain incompletely defined. This study tested membrane-associated RING-CH 7 (MARCH7) as a direct miR-155 target and examined associated molecular and cellular phenotypes in MCF-7 and MDA-MB-231 breast cancer cells. Basal miR-155 expression was assessed in MCF-10A, MCF-7, and MDA-MB-231 cells. MCF-7 cells were analyzed by MTT, RT-qPCR, Western blotting, bioinformatic prediction, dual-luciferase reporter assays, and MARCH7 knockdown; MDA-MB-231 cells were additionally evaluated by MTT, RT-qPCR, wound-healing, and Transwell invasion assays. miR-155 was more abundant in the breast cancer cell lines than in MCF-10A cells. In MCF-7 cells, miR-155 overexpression increased MTT-derived metabolic viability, reduced MARCH7 and PTEN expression, increased Cyclin D1, reduced cleaved caspase-3, and was associated with increased PI3K and AKT phosphorylation. In MDA-MB-231 cells, RT-qPCR confirmed successful miR-155 modulation, whereas MTT changes were modest; these small changes may reflect either model/endpoint differences or limited sensitivity of the MTT assay under the tested conditions. Dual-luciferase assays confirmed direct targeting of the MARCH7 3′-UTR by miR-155, while miR-155 inhibition markedly reduced MDA-MB-231 migration and invasion. These findings establish MARCH7 as a direct miR-155 target in the models examined. The PTEN/PI3K/AKT changes are associated downstream findings and are not yet proven to be mediated specifically by MARCH7.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Technology, School of Medicine, Shaoguan University, Shaoguan 512026, China.
- Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia.
- Department of Nursing, School of Medicine, Shaoguan University, Shaoguan 512026, China.
ORCID-Profile: Xiaohua Chen
Förderung
- Shaoguan University
- 2023 Shaoguan Social Development Science and Technology Collaborative Innovation System Project Supporting Scientific Researchers
- 2023 Shaoguan Social Development Science and Technology Collaborative Innovation System Project for Supporting Scientific Researchers
- 2023 University-level Quality Engineering Construction Project of Shaoguan University
Zitieren
APA
Chen, X., Qiu, H., Chen, F., Cao, Y., & Rao, L. (2026). miR-155 Directly Targets MARCH7 and Modulates Viability and Invasive Phenotypes in Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188092
Vancouver
Chen X, Qiu H, Chen F, Cao Y, Rao L. miR-155 Directly Targets MARCH7 and Modulates Viability and Invasive Phenotypes in Breast Cancer Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188092
BibTeX
@article{Chen2026,
author = {Chen, Xiaohua and Qiu, Huayun and Chen, Fangying and Cao, Yue and Rao, Lei},
title = {miR-155 Directly Targets MARCH7 and Modulates Viability and Invasive Phenotypes in Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188092}
}
EUVIMED